Biohaven BHVN Business Segments — Non-operating income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biohaven in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biohaven's business segments — non-operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biohaven's business segments — non-operating income?
- Biohaven (BHVN) reported business segments — non-operating income of -$168K in Q1 2026.
- How has Biohaven's business segments — non-operating income changed year-over-year?
- Biohaven's business segments — non-operating income increased by 65.9% year-over-year, from -$493K to -$168K.
- What is the long-term trend for Biohaven's business segments — non-operating income?
- Over 2 years (2022 to 2024), Biohaven's business segments — non-operating income has grown at a 354.4% compound annual growth rate (CAGR), from $1.91M to -$39.42M.
- What does business segments — non-operating income mean?
- Includes financial gains or losses derived from activities outside of the company's core biopharmaceutical operations, such as interest income or investment returns. This metric provides a view of the segment's secondary revenue streams and financial management performance. It is important for assessing the overall financial health beyond core drug development.